Isotechnika, Inc

Isotechnika Receives No Objection Letter From Health Canada for Phase IIb Kidney Transplant Trial

Isotechnika Inc. announced today that the Company received a No Objection Letter from Health Canada for the commencement of a Phase IIb kidney transplant trial for its lead immunosuppressive drug, ISA247.

OTE0006
28.04.2005 14:01
 

Isotechnika Receives U.S. Patent for Insulin Resistance Diagnostic Test

Isotechnika Inc. (TSX: ISA) announced today that the Company has been issued U.S.

OTE0004
06.04.2005 14:10